Guangzhou Sino-Israel Biotech Investment Fund (GIBF) News
4 articles
growth-positive
"עולם הבריאות הסיני נמצא בתהליך התפתחות מואץ"
GIBF, a Chinese-Israeli fund that invests in Israeli companies and establishes subsidiaries in China, recently completed a $300 million funding round for its second fund. The fund, which operates from the Guangzhou province in China, identifies Israeli companies with technologies relevant to the Chinese market, primarily in the health sector. It then establishes subsidiaries in China in joint ownership with the Israeli start-up, building their operations in China with a view to an exit or IPO on the Chinese stock exchange. The new fund will not only focus on medical equipment but also on pharma and digital health.
InvestmentExpand
growth-positive
Shuki Gleitman's GIBF raising $300 million in China for second biotech fund
The Guangzhou Sino-Israel Biotech Investment Fund (GIBF) is raising $300 million for its second fund, with commitments already secured for $200 million. The fund focuses on investing in Israeli biotech companies and has previously invested in eight companies, including InMode. GIBF plans to invest in biomed companies in its second fund, targeting companies in the second or third stage of clinical trials. The fund aims to invest between $15-20 million in each company. GIBF is the only foreign-run Chinese fund with a license to make private equity investments in China. The funds partners include Shuki Gleitman, Avner Lushi, Prof. Avraham Karasik, Prof. Shlomo Noy, and Carl Geng.
InvestmentPartners
growth-positive
Israel-China medical fund to raise $300m for joint drug development ventures
The Guangzhou Sino-Israel Bio-industry Investment Fund (GIBF) is raising a second fund of $300 million to promote and invest in Chinese and Israeli joint ventures in the biomedical field. The fund has already closed $200 million and plans to raise an additional $100 million. GIBF helps set up Chinese joint ventures with foreign companies, mainly Israeli, and focuses on Israeli and European biotechnology companies in phase 2-3 of clinical trials. The fund will enable these companies to perform clinical trials in China and recruit Chinese patients. GIBF 1, the first fund, has made eight investments in Israeli companies in the medical devices and digital health field. Despite challenges from the pandemic and investment environment, GIBF has been able to continue its activities with government support and local team in China.
InvestmentPartners
growth-positive
Ex-Israeli chief scientist helping Guangzhou jumpstart its tech ecosystem
The Guangzhou Municipal Government is partnering with Yehoshua Gleitman, former chief scientist of Israel, to create a startup ecosystem in Guangzhou. The government aims to turn the city into a tech powerhouse and boost innovation in various sectors. They have asked Gleitman to collaborate on setting up a local incubator program, similar to those he helped establish in Israel. The program will provide investment grants for projects in both China and Israel. The focus of the incubation center will be on life sciences and biotechnology firms. This collaboration is an extension of an existing partnership between Gleitman, Israeli entrepreneurs, and the Guangzhou Municipal Government. The partnership includes the Guangzhou-Israel Sino Bio-industry Investment Fund, which seeks to invest in Chinese subsidiaries of Israeli biomedical companies.
PartnersInvestment
